Please ensure Javascript is enabled for purposes of website accessibility

Medtronic's Bladder-Control Devices Have a Feisty New Competitor

By Cory Renauer - Mar 5, 2020 at 6:13PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The new rechargeable nerve stimulator from Axionics Modulation Technologies is giving the industry giant more competition than expected.

During a recent earnings call, the CEO of Axonics Modulation Technologies (AXNX 4.48%) offered an enthusiastic outlook for the company's recently launched bladder-control device, r-SNM.

In the market for bladder and bowel dysfunction devices that stimulate the sacral nerve, the world's largest medical-device maker Medtronic (MDT -0.96%) currently holds a leading share. 

A good start 

In November, the Food and Drug Administration (FDA) approved r-SNM, the first rechargeable sacral nerve stimulator cleared for full-body MRI scans, and sales results from the initial launch were surprisingly good. Sales of r-SNM reached $9.9 million before the end of 2019, and the company expects momentum to continue throughout 2020. 

Man in nursing home bed being helped up by aide.

Image source: Getty Images.

In 2020, over 300 U.S. institutions have already implanted an r-SNM system, compared to just 200 during the fourth quarter of 2019. At a recent conference, Axionics was able to show a crowd of physicians results from a clinical study that showed that implanting an r-SNM device helped 9 out of 10 patients achieve clinically meaningful improvement.

Trouble ahead?

In the EU, Medtronic has already launched a device expected to pour water on Axonics' r-SNM launch. The InterStim Micro from Medtronic is a rechargeable implant designed to be safe during full-body MRI scans. In the U.S., Medtronic submitted an application for InterStim Micro last October, which means it could begin pressuring Axonics sales in the summer.

Luckily for Medtronic and Axonics, there's probably more-than-enough underserved patients with incontinence issues to fuel sales of at least two successful devices. Overactive bladder affects an estimated 87 million adults in the U.S. and EU, and another 40 million lack bowel control. 

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Axonics Modulation Technologies, Inc. Stock Quote
Axonics Modulation Technologies, Inc.
AXNX
$62.94 (4.48%) $2.70
Medtronic plc Stock Quote
Medtronic plc
MDT
$89.62 (-0.96%) $0.87

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
322%
 
S&P 500 Returns
113%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 07/07/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.